Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

A scientist with pill bottles in front of FDA headquarters

Regulatory

FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir.

June 2, 2025

6 min read

Tristan Manalac

Opinion

Opinion: New FDA Guidelines Raise the Bar on Nitrosamine Testing for Pharma Industry

Here’s how companies can ensure they’re in compliance with new requirements that go into effect in August.

June 2, 2025

6 min read

Shankar Sankaran

Cancer

Jazz Is in the “Goldilocks Zone” With New Cancer Data at ASCO25

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through Jazz Pharmaceuticals’ dealmaking over the last five years.

May 31, 2025

3 min read

Dan Samorodnitsky

Illustration showing line of people leaving, standing on top of hand pointing their way out

Layoffs

Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified a potential accelerated approval pathway. The company has pared down its staff to conserve resources to fund a potential resubmission.

May 30, 2025

2 min read

Angela Gabriel

Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.

Immunology and inflammation

Sanofi, Regeneron Shares Tumble as Dupixent Follow-Up Fails Phase III COPD Test

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their blockbuster Dupixent in the I&I space, was “contrary to our expectations—we were wrong.”

May 30, 2025

3 min read

Annalee Armstrong

Lung Cancer

Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations.

May 30, 2025

3 min read

Nick Paul Taylor

Contemporary art collage. Businessman putting voting paper into ballot box sticking out from retro computer motinor. Choosing right candidate to run he company. Online voting, election concept

Diversity, equity & inclusion

Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI goals in executive pay incentives.

May 30, 2025

3 min read

Annalee Armstrong

Collaboration

Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric cancer and pancreatic cancer.

May 30, 2025

2 min read

Tristan Manalac